Members |
targetComponentId |
Bupivacaine hydrochloride 0.1% infusion solution |
Bupivacaine only product in parenteral dose form |
Bupivacaine hydrochloride 0.125% infusion solution 250mL bag |
Bupivacaine hydrochloride 1.25 mg/mL solution for injection |
Bupivacaine hydrochloride 0.5%/epinephrine 50micrograms 10mL (1:200000) injection solution |
Product containing precisely bupivacaine hydrochloride 5 milligram/1 milliliter and epinephrine (as epinephrine bitartrate) 5 microgram/1 milliliter conventional release solution for injection (clinical drug) |
Bupivacaine hydrochloride 0.75% injection |
Bupivacaine only product in parenteral dose form |
Bupivacaine hydrochloride 0.75% injection solution ampule |
Bupivacaine only product in parenteral dose form |
Bupivacaine hydrochloride 2.5mg/epinephrine bitartrate 5mcg injection solution vial |
Product containing only bupivacaine and epinephrine (medicinal product) |
Bupivacaine hydrochloride 5mg/epinephrine 5mcg injection solution vial |
Product containing precisely bupivacaine hydrochloride 5 milligram/1 milliliter and epinephrine (as epinephrine bitartrate) 5 microgram/1 milliliter conventional release solution for injection (clinical drug) |
Bupivacaine hydrochloride 7.5mg/dextrose 82.5mg injection solution vial |
Bupivacaine only product in parenteral dose form |
Bupivacaine hydrochloride+epinephrine 0.75%/1:200000 injection |
Adrenaline (as adrenaline acid tartrate) 5 microgram/mL and bupivacaine hydrochloride 7.5 mg/mL solution for injection |
Buprenorphine + naloxone withdrawal |
Buprenorphine and/or naloxone withdrawal |
Buprenorphine 5microgram/hour transdermal patch |
Product containing only buprenorphine in transdermal dose form (medicinal product form) |
Buprenorphine hydrochloride + naloxone hydrochloride |
Product containing buprenorphine and naloxone (medicinal product) |
Buprenorphine hydrochloride 2mg + naloxone hydrochloride 0.5mg sublingual tablet |
Buprenorphine 2 mg and naloxone hydrochloride 500 microgram sublingual tablet |
Buprenorphine hydrochloride 8mg + naloxone hydrochloride 2mg sublingual tablet |
Buprenorphine (as buprenorphine hydrochloride) 8 mg and naloxone hydrochloride 2 mg sublingual tablet |
Bupropion hydrochloride 100mg m/r tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
Bupropion hydrochloride 100mg prolonged-release oral tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
Bupropion hydrochloride 200mg m/r tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
Bupropion hydrochloride 200mg prolonged-release oral tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
Bupropion hydrochloride 300mg m/r tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
Bupropion hydrochloride 300mg prolonged-release oral tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
Bupropion hydrochloride 50mg m/r tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
Bupropion hydrochloride 50mg prolonged-release oral tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
Burkholderia |
Genus Burkholderia (organism) |
Burkholderia cocovenenans |
Burkholderia gladioli |
Burkholderia vandii |
Burkholderia plantarii |
Burkitt lymphoma of lymph nodes of axilla and upper limb |
Burkitt lymphoma of lymph nodes of upper limb (disorder) |
Burkitt lymphoma of lymph nodes of inguinal region and lower limb |
Burkitt lymphoma of lymph nodes of lower limb (disorder) |
Burkitt's tumor of extranodal AND/OR solid organ site |
Burkitt's lymphoma (clinical) |
Burkitt's tumor of lymph nodes of axilla AND/OR upper limb |
Burkitt lymphoma of lymph nodes of upper limb (disorder) |
Burkitt's tumor of lymph nodes of inguinal region AND/OR lower limb |
Burkitt lymphoma of lymph nodes of lower limb (disorder) |
Burn involving 10-14 percent of body surface, with 10-14 percent of body surface with full thickness burn |
Burn involving 10-19 percent of body surface, with 10-14 percent of body surface with full thickness burn (disorder) |
Burn involving 15-19 percent of body surface, with 10-19 percent of body surface with full thickness burn |
Burn involving 10-19 percent of body surface, with 15-19 percent of body surface with full thickness burn (disorder) |
Burn of larynx, trachea AND/OR lung |
Burn |
Burn of other internal organ, NEC |
Burn of internal organ |
Burn to cornea - erythema |
Corneal burn |
Burn to cornea - erythema |
Corneal burn |
Buserelin 150micrograms spray |
Buserelin only product |
Buspirone hydrochloride 5mg tablet |
Buspirone hydrochloride 5 mg oral tablet |
Buspirone hydrochlorine |
Buspirone hydrochloride (substance) |
Butabarbital sodium 30mg/5mL elixir |
Product containing precisely secbutabarbital sodium 6 milligram/1 milliliter conventional release oral solution (clinical drug) |
Butorphanol tartrate 1mg/mL injection solution ampule |
Butorphanol tartrate 1 mg/mL solution for injection |
Butorphanol tartrate 2mg/mL injection solution ampule |
Butorphanol only product in parenteral dose form |
Buttock random pattern flap |
Random pattern flap |
Button battery causing toxic effect |
Toxic effect of sulfuric acid |
Butyl nitrate - non-pharmaceutical |
Butyl nitrate |
Butyrophenone derivative antipsychotic agent |
Butyrophenone derivative |
Butyrophenone poisoning NOS |
Poisoning by butyrophenone-based tranquilizer |
Bypass of organ NOC |
Construction of shunt |
Byrd respirator therapy |
Respiratory therapy |
C/O - specified symptom findings |
Finding reported by subject or history provider (finding) |
C1 esterase inhibitor 500 units powder for injection solution 8mL vial |
Product containing precisely human C1 esterase inhibitor 500 unit/1 vial powder for conventional release solution for injection (clinical drug) |
CDC Corynebacterium group G-1 |
Corynebacterium accolens |
CDC group DF-2 |
Capnocytophaga canimorsus |
CDE genotype |
CDE haplotype (finding) |
CDe genotype |
CDe haplotype (finding) |
CTV3 ROOT |
SNOMED CT Concept |
Cabbage - dietary |
Cabbage (substance) |
Cabergoline [parkinsons] |
Product containing cabergoline (medicinal product) |
Caesarean delivery - delivered |
Deliveries by caesarean |
Caffeine and sodium benzoate injection |
Product containing caffeine and sodium benzoate (medicinal product) |
Caffeine containing substance - non-pharmaceutical |
Caffeine |
Café-au-lait spots and ring chromosome 11 |
Ring chromosome 11 syndrome |
Calcipotriene 0.005%/betamethasone 0.064% topical suspension |
Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 milliliter and calcipotriol 50 microgram/1 milliliter conventional release cutaneous lotion (clinical drug) |
Calcitonin, salmon 100unit/mL injection solution 1mL vial |
Product containing precisely salmon calcitonin 100 unit/1 milliliter conventional release solution for injection (clinical drug) |
Calcitonin, salmon 200iu/mL spray |
Product containing precisely salmon calcitonin 200 unit/1 actuation conventional release nasal spray (clinical drug) |
Calcitonin, salmon 200unt/mL injection |
Salmon calcitonin 200 unit/mL solution for injection |
Calcitonin, salmon 200unt/mL injection solution 2mL vial |
Salmon calcitonin 200 unit/mL solution for injection |
Calcium analyte |
Calcium |
Calcium antacid |
Calcium compound |
Calcium carbonate+cholecalciferol 1.25g/11micrograms/sachet granules |
Calcium carbonate 6.25 mg/mL and colecalciferol 2.2 unit/mL oral solution |
Calcium chloride 10% injection solution 10mL prefilled syringe |
Product containing precisely calcium chloride 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Calcium hydroxyapatite microsphere suspension in aqueous based carrier 0.3mL prefilled syringe |
Hydroxyapatite only product in parenteral dose form |
Calcium hydroxyapatite microsphere suspension in aqueous based carrier 1.3mL prefilled syringe |
Hydroxyapatite only product in parenteral dose form |
Calcium phosphate+colecalciferol 3100mg/20micrograms/sachet powder for oral suspension |
Calcium phosphate and colecalciferol only product |
Calculus - composition |
Calculus chemical composition - finding |
Calculus exam. general |
Calculus examination |
Calculus examination NOS |
Calculus examination |
Calculus examination NOS |
Calculus examination |
Calculus examination general |
Calculus examination |
Calculus gen. exam. NOS |
Calculus examination |
Calculus general examination NOS |
Calculus examination |
Calfactant intratracheal suspension 6mL vial |
Product containing only calfactant (medicinal product) |
Calicivirus group |
Family Caliciviridae (organism) |
Calliphora erythrocephala |
Calliphora vicina |
Callitrogae |
Genus Cochliomyia (organism) |
Caloric intake, function (observable entity) |
Energy intake (observable entity) |
Caloscypha fulgens |
Caloscypha fulgens (organism) |
Calymmatobacterium granulomatis |
Klebsiella granulomatis (organism) |
Camouflaging preparations adverse reaction |
Adverse reaction (disorder) |
Campylobacter cinaedi |
Helicobacter cinaedi |
Campylobacter fennelliae |
Helicobacter fennelliae |
Campylobacter laridis |
Campylobacter lari |
Campylobacter laridis rRNA |
Campylobacter lari rRNA |
Campylobacter laridis rRNA assay |
Campylobacter lari rRNA assay |
Campylobacter nitrofigilis |
Arcobacter nitrofigilis (organism) |
Canakinumab 150mg powder for injection solution |
Canakinumab only product |
Cancer care plan |
Cancer care plan |
Cancer care plan |
Cancer care plan |
Cancer care plan |
Cancer care plan |
Cancer care review |
Cancer care review (procedure) |
Cancer cervix - screening done |
Screening for malignant neoplasm of cervix done (situation) |